Company / Accounts Receivable
Cocrystal Pharma, Inc. Accounts Receivable History
FY2012-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$556.0K
FY2020
5-year range
$556.0K / $835.0K
FY2016-FY2020
Trend
-13.7%
vs FY2019
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $834,998 to $556,000 over the past 8 years.
Based on SEC 10-K filings.
$556,000 in FY2020.
Declined from $834,998 to $556,000 over the past 8 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2020, accounts receivable decreased 13.7% year-over-year.
Company context
Key Data Points
- Altman Z-Score 14.87 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2021 | - | - |
| FY2020 | $556.0K | -13.7% |
| FY2019 | $644.0K | -22.9% |
| FY2012 | $835.0K | - |
As of FY2020 · SEC 10-K · Updated Jun 24, 2026